Table SII. Comparison of cardiovascular risk factors between female rosacea cases and controls

	Rosacea cases (*n* = 146)	Controls (*n* = 278)	*p*-value
Body mass index, kg/m^2, mean (SD)	26.50 (4.66)	26.13 (4.48)	0.419
Body mass index, *n* (%)			0.234
Underweight (< 18.5)	24 (1.3)	0 (0)	
Normal (18.5–24.9)	65 (44.5)	135 (48.6)	
Overweight (25.0–29.9)	48 (32.9)	87 (31.3)	
Obese (≥30.0)	31 (21.2)	56 (20.1)	
Body composition, mean (SD)			
Fat percentage	33.47 (7.69)	33.00 (7.71)	0.516
Fat mass, kg	24.64 (9.75)	23.91 (9.52)	0.438
Skeletal muscle mass, kg	25.73 (3.47)	25.47 (3.12)	0.661
Visceral fat area, cm^2	106.22 (79.54, 133.15)	99.87 (79.48, 128.92)	0.384
Waist circumference, cm	87.2 (12.1)	86.3 (11.6)	0.513
Hip circumference, cm	101.1 (9.4)	100.6 (9.2)	0.638
Waist:hip ratio	0.9 (0.1)	0.9 (0.1)	0.360
Insulin levels in OGTT, mU/l, median (IQR)			
Fasting	7.85 (5.27, 12.07)	6.50 (4.80, 9.72)	**0.020**
30 min	57.80 (42.70, 95.00)	52.50 (39.00, 82.15)	0.089
60 min	58.80 (41.90, 112.38)	55.10 (37.52, 95.12)	0.097
120 min	46.85 (33.20, 87.88)	41.80 (29.93, 59.23)	**0.029**
Glucose levels in OGTT, mmol/l			
Fasting	5.30 (5.00, 5.70)	5.30 (5.00, 5.60)	0.666
30 min	7.50 (6.50, 8.55)	7.50 (6.50, 8.50)	0.826
60 min	6.50 (5.10, 8.30)	6.70 (5.30, 7.93)	0.760
120 min	5.80 (4.95, 6.85)	5.80 (5.03, 6.60)	0.784
Glucose tolerance status, *n* (%)			0.148
Normal (< 6.1 mmol/l)	96 (78.0)	195 (83.7)	
Impaired fasting glucose (6.1–6.9 mmol/l)	7 (5.7)	7 (3.0)	
Impaired glucose tolerance (≥7.0 mmol/l)	11 (8.9)	16 (6.9)	
Screen detected DM[a]	8 (6.5)	7 (3.0)	
Previous DM	1 (0.8)	8 (3.4)	
Fasting plasma glucose, mmol/l	5.20 (4.90, 5.70)	5.15 (4.82, 5.50)	0.301
Fasting indices, median (IQR)			
HOMA2 β cell function	80.80 (63.40, 97.80)	78.00 (64.05, 97.25)	0.656
HOMA2 insulin resistance	0.90 (0.62, 1.31)	0.84 (0.63, 1.16)	0.299
B-HbA1c, (%)	5.40 (5.10, 5.60)	5.40 (5.10, 5.60)	0.831
HbA1c, mmol/mol	35.00 (32.25, 38.00)	35.00 (32.00, 38.00)	0.952
Fasting serum lipids, mmol/l			
Total cholesterol	5.20 (0.80)	5.15 (0.81)	0.491
HDL	1.68 (0.40)	1.67 (0.39)	0.879
LDL	3.23 (0.78)	3.20 (0.77)	0.725
Triglycerides	1.10 (0.59)	1.07 (0.57)	0.647
Dyslipidemia treatment, *n* (%)			1.000
No	142 (98.6)	260 (98.1)	
Yes	2 (1.4)	5 (1.9)	
Hypertension treatment, *n* (%)			0.300
No	123 (85.4)	237 (89.4)	
Yes	21 (14.6)	28 (10.6)	
Blood pressure, mmHg, mean (SD)			
Systolic mean, min	121.61 (15.47)	118.62 (15.07)	0.056
Diastolic mean, min	83.78 (9.96)	82.09 (10.19)	0.104
High sensitivity CRP, mg/l	1.9 (3.5)	1.4 (2.3)	0.102
High sensitivity CRP, mg/l, *n* (%)			0.240
< 1%	79 (54.5)	162 (59.1)	
1–3%	45 (31.0)	87 (31.8)	
> 3%	21 (14.5)	25 (9.1)	
Cardiovascular risk scores, median (IQR)			
Framingham Risk Score	3.20 (2.30, 4.57)	3.00 (2.20, 4.20)	0.117
FINRISK	0.90 (0.70,1.30)	0.90 (0.70, 1.20)	0.462
SCORE, %	0.24 (0.19, 0.30)	0.22 (0.17, 0.31)	0.147
Fatty liver index	0.46 (0.13, 1.58)	0.28 (0.13, 1.20)	0.175
CIMT (average), mm	0.61 (0.56, 0.66)	0.59 (0.55, 0.64)	**0.027**
Serum SHBG, nmol/l	54.2 (29.4)	57.6 (29.6)	0.156
Serum total testosterone, nmol/l	0.82 (0.61, 1.02)	0.72 (0.54, 0.91)	**0.003**
Free testosterone concentration, nmol/l	0.011 (0.008, 0.014)	0.009 (0.007, 0.013)	**<0.001**
Bioavailybility testosterone	0.270 (0.200, 0.340)	0.220 (0.170,0.310)	**<0.001**
Free androgen index	1.69 (1.19, 2.35)	1.37 (0.95, 2.03)	**<0.001**

[a]Diabetes diagnosed during the 46-year follow-up study.
CIMT: carotid intima-media thickness; CRP: C-reactive protein test; DM: diabetes mellitus; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein; HOMA: homeostatic model assessment; LDL: low-density lipoprotein; mmHg: millimeters mercury; OGTT: oral glucose tolerance test; SHBG: sex hormone-binding globulin: SD: standard deviation; IQR: interquartile range.